prednisone has been researched along with everolimus in 34 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.94) | 18.2507 |
| 2000's | 7 (20.59) | 29.6817 |
| 2010's | 25 (73.53) | 24.3611 |
| 2020's | 1 (2.94) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Appel-Dingemanse, S; Carter, C; Kahan, BD; Katz, SH; Van Buren, CT; Von Fellenberg, J; Wong, RL | 1 |
| Ettenger, RB; Grimm, EM | 1 |
| Budde, K; Figueiredo, J; Golor, G; Hartmann, S; Kovarik, JM; Lison, A; Neumayer, HH; Rordorf, C | 1 |
| Boger, R; Hoyer, PF; Kranz, B; Vester, U; Wehr, S | 1 |
| Ader, JL; Allard, J; Durand, D; Kamar, N; Ribes, D; Rostaing, L | 1 |
| Abecassis, M; Calmus, Y; Fischer, L; Freeman, R; Klempnauer, J; Langnas, A; Levy, G; Mayer, D; Nashan, B; Neuhaus, P; Punch, J; Roberts, J; Rogiers, X; Samuel, D; Schmidli, H; Sloof, M; Tuttle-Newhall, E | 1 |
| Altieri, P; Carmellini, M; Corbetta, G; Cossu, M; Iorio, B; Montagnino, G; Ponticelli, C; Rigotti, P; Salvadori, M; Sandrini, S; Schena, FP; Stefoni, S | 1 |
| Delgado, DH; Gustafsson, F; Rao, V; Ross, HJ; Sheedy, J; Sheshgiri, R | 1 |
| Felipe, CR; Mandia-Sampaio, EL; Medina-Pestana, JO; Park, SI; Spinelli, GA; Tedesco-Silva, H | 1 |
| Felipe, CR; Medina Pestana, JO; Schmouder, RL; Slade, A; Tedesco-Silva, H | 1 |
| Cardona, M; Castel, MÁ; Farrero, M; Pérez-Villa, F | 1 |
| Faria, E; Matin, SF; Rao, P; Turturro, F | 1 |
| Eom, HS; Huh, J; Kang, HJ; Kim, JS; Kim, SJ; Kim, WS; Ko, YH; Lee, J; Lee, SS; Lee, SY; Park, WS; Suh, C; Yang, WI; Yim, DS | 1 |
| Belingheri, M; Cardillo, M; Dello Strologo, L; Ferraresso, M; Ghio, L; Ghirardo, G; Ginevri, F; Guzzo, I; Innocente, A; Murer, L; Parodi, A | 1 |
| Citterio, F; Favi, E; Pedroso, JA; Romagnoli, J; Salerno, MP; Spagnoletti, G | 1 |
| Aguiar, W; Campos, E; Cristelli, M; Felipe, C; Ferreira, A; Franco, M; Gerbase-DeLima, M; Medina-Pestana, J; Oliveira, N; Sandes-Freitas, T; Tedesco-Silva, H | 1 |
| Dickow, B; Fontana, J; Heath, E; Heilbrun, L; Land, S; Li, J; Shevrin, D; Smith, D; Stark, K; Stein, M; Vaishampayan, U | 1 |
| Do, YR; Eom, HS; Hong, M; Kang, HJ; Kim, JS; Kim, SJ; Kim, WS; Ko, YH; Lee, H; Lee, SH; Lee, WS; Shin, DY; Suh, C; Yoo, HY; Yoon, DH | 1 |
| Aguiar, W; Campos, E; Cristelli, M; Felipe, C; Ferreira, A; Franco, M; Gerbase de Lima, M; Hannun, P; Medina-Pestana, J; Sandes-Freitas, T; Tedesco-Silva, H | 1 |
| Baranowska-Bosiacka, I; Ciechanowski, K; Domański, L; Gołembiewska, E; Kabat-Koperska, J; Kędzierska, K; Kolasa-Wołosiuk, A; Kosik-Bogacka, D; Pilutin, A; Safranow, K | 1 |
| Ansell, SM; Colgan, JP; Habermann, TM; Inwards, DJ; Johnston, PB; LaPlant, B; McPhail, E; Micallef, IN; Nowakowski, GS; Witzig, TE | 2 |
| Aguiar, W; Basso, G; Cristelli, M; Felipe, C; Ferreira, A; Hannun, P; Mansur, J; Medina-Pestana, J; Tedesco Silva, H; Ueno, P; Viana, L | 1 |
| Baranowska-Bosiacka, I; Ciechanowski, K; Gołembiewska, E; Gutowska, I; Kabat-Koperska, J; Kędzierska, K; Kolasa-Wołosiuk, A; Kosik-Bogacka, D; Pilutin, A; Safranow, K | 1 |
| Aboukameel, A; Azmi, AS; Baloglu, E; Bhutani, D; Carlson, R; Elloul, S; Kauffman, M; Mohammad, RM; Muqbil, I; Senapedis, W; Shacham, S; Zonder, J | 1 |
| Aguiar, W; Basso, G; Bessa, A; Campos, E; Cristelli, M; Felipe, C; Ferreira, A; Gerbase-DeLima, M; Ivani, M; Mansur, J; Medina-Pestana, J; Proença, H; Ruppel, P; Stopa, S; Tedesco-Silva, H; Viana, L | 1 |
| Amadori, D; Barone, D; Burgio, SL; De Giorgi, U; Gallà, V; Lolli, C; Maugeri, A; Schepisi, G; Vertogen, B | 1 |
| Belada, D; Bermudez Silva, CD; Bouabdallah, K; Cavalli, F; Costa, LJ; Fan, J; Fayad, L; Hino, M; Ikeda, T; Kattan, JG; Kim, WS; Kuruvilla, J; Larouche, JF; Louveau, AL; Mayer, J; Ogura, M; Ozcan, M; Rigacci, L; Shi, Y; Tobinai, K; Vanazzi, A; Voi, M; Witzig, TE; Wu, C; Zhu, J | 1 |
| Demir, E; Karaoglan, C; Sair, B; Sever, MS; Turkmen, A; Yazici, H; Yegen, G | 1 |
| Till, BG | 1 |
| Aguiar, W; Cristelli, M; de Marco, R; de Paula, M; Felipe, CR; Ferreira, AN; Gerbase-DeLima, M; Mansur, J; Medina-Pestana, J; Proença, H; Tedesco-Silva Junior, H; Viana, L; Wagner, D | 1 |
| Cristelli, MP; de Azevedo, VFD; de Paula, MI; Felipe, CR; Medina-Pestana, JO; Prizmic, PSS; Tavares, MG; Tedesco-Silva Junior, H; Viana, LA; Wagner de Castro Lima Santos, D | 1 |
| Felipe, CR; Medina Pestana, JO; Miranda, TA; Santos, RHN; Tedesco-Silva Junior, H | 1 |
3 review(s) available for prednisone and everolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients.
Topics: Adolescent; Age Factors; Azathioprine; Child; Child, Preschool; Clinical Trials as Topic; Cyclosporins; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Everolimus; Graft Rejection; Graft Survival; Half-Life; Humans; Immunosuppressive Agents; Intestinal Absorption; Kidney Transplantation; Prednisone; Sirolimus; Treatment Outcome | 2001 |
Maintenance Therapy in Diffuse Large B Cell Lymphoma and Mantle Cell Lymphoma.
Topics: Adenine; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Cyclophosphamide; Doxorubicin; Everolimus; Female; Hematopoietic Stem Cell Transplantation; Humans; Lenalidomide; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Maintenance Chemotherapy; Male; Middle Aged; Neoplasm Recurrence, Local; Piperidines; Prednisone; Pyrazoles; Pyrimidines; Rituximab; Vincristine; Young Adult | 2018 |
20 trial(s) available for prednisone and everolimus
| Article | Year |
|---|---|
A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients.
Topics: Adult; Aged; Cyclosporine; Double-Blind Method; Drug Administration Schedule; Everolimus; Female; Glucocorticoids; Half-Life; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Prednisone; Retreatment; Sirolimus | 1999 |
Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants.
Topics: Administration, Oral; Adult; Area Under Curve; Biological Availability; Cross-Over Studies; Cyclosporine; Dietary Fats; Drug Interactions; Everolimus; Fasting; Half-Life; Headache; Humans; Immunosuppressive Agents; Kidney Transplantation; Middle Aged; Prednisone; Sirolimus; Time Factors | 2002 |
Everolimus (Certican) in combination with neoral in pediatric renal transplant recipients: interim analysis after 3 months.
Topics: Adolescent; Child; Cyclosporine; Drug Therapy, Combination; Ethnicity; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Prednisone; Sirolimus; Time Factors | 2002 |
Assessment of glomerular and tubular functions in renal transplant patients receiving cyclosporine A in combination with either sirolimus or everolimus.
Topics: Adult; Cyclosporine; Drug Therapy, Combination; Everolimus; Female; Follow-Up Studies; Glomerular Filtration Rate; Glucocorticoids; Humans; Immunosuppressive Agents; Kidney Transplantation; Kidney Tubules; Male; Middle Aged; Prednisone; Sirolimus; Time Factors | 2005 |
Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results.
Topics: Adult; Cholesterol; Cholesterol, LDL; Creatinine; Cyclosporine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Everolimus; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Incidence; Kidney; Leukopenia; Liver Transplantation; Longitudinal Studies; Male; Middle Aged; Prednisone; Sirolimus; Thrombocytopenia; Treatment Outcome; Triglycerides | 2006 |
A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine.
Topics: Adult; Cyclosporine; Everolimus; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Prednisone; Sirolimus | 2008 |
Chronopharmacokinetics of mycophenolic acid and its glucuronide and acyl glucuronide metabolites in kidney transplant recipients converted from cyclosporine to everolimus.
Topics: Adrenal Cortex Hormones; Adult; Biotransformation; Circadian Rhythm; Cross-Over Studies; Cyclosporine; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Everolimus; Female; Glucuronides; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Prednisone; Prodrugs; Sirolimus; Tablets, Enteric-Coated | 2012 |
A phase I study of everolimus and CHOP in newly diagnosed peripheral T-cell lymphomas.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Drug Administration Schedule; Everolimus; Humans; Lymphoma, T-Cell, Peripheral; Maximum Tolerated Dose; Prednisone; Sirolimus; Vincristine | 2013 |
Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
Topics: Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Basiliximab; Cytomegalovirus Infections; Dose-Response Relationship, Drug; Drug Therapy, Combination; Everolimus; Female; Graft Rejection; Humans; Immunosuppressive Agents; Incidence; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Postoperative Complications; Prednisone; Prospective Studies; Recombinant Fusion Proteins; Sirolimus; Tacrolimus; Treatment Outcome | 2015 |
Phase II Trial of Carboplatin, Everolimus, and Prednisone in Metastatic Castration-resistant Prostate Cancer Pretreated With Docetaxel Chemotherapy: A Prostate Cancer Clinical Trial Consortium Study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease Progression; Docetaxel; Everolimus; Humans; Male; Neoplastic Cells, Circulating; Phosphorylation; Prednisone; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Proto-Oncogene Proteins c-akt; Survival Rate; Taxoids; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 1 Protein; Tumor Suppressor Proteins | 2015 |
A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Drug Administration Schedule; Everolimus; Female; Humans; Lymphoma, T-Cell, Peripheral; Male; Middle Aged; Neoplasm Staging; Prednisone; PTEN Phosphohydrolase; TOR Serine-Threonine Kinases; Treatment Outcome; Vincristine | 2016 |
Everolimus combined with R-CHOP-21 for new, untreated, diffuse large B-cell lymphoma (NCCTG 1085 [Alliance]): safety and efficacy results of a phase 1 and feasibility trial.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Everolimus; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Staging; Polyethylene Glycols; Prednisone; Prognosis; Recombinant Proteins; Rituximab; Survival Rate; Vincristine | 2016 |
Wound Healing Complications in Kidney Transplant Recipients Receiving Everolimus.
Topics: Adult; Antibodies, Monoclonal; Antilymphocyte Serum; Basiliximab; Brazil; Drug Therapy, Combination; Everolimus; Female; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Prednisone; Prospective Studies; Recombinant Fusion Proteins; Risk Factors; Tacrolimus; Time Factors; Treatment Outcome; Ultrasonography; Wound Healing | 2017 |
Donor-Specific Anti-Human Leukocyte Antigens Antibodies, Acute Rejection, Renal Function, and Histology in Kidney Transplant Recipients Receiving Tacrolimus and Everolimus.
Topics: Adult; Allografts; Antibodies, Monoclonal; Antilymphocyte Serum; Basiliximab; Biopsy; Drug Therapy, Combination; Everolimus; Female; Glomerular Filtration Rate; Graft Rejection; Graft Survival; HLA Antigens; Humans; Immunosuppressive Agents; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Prednisone; Prospective Studies; Recombinant Fusion Proteins; Retrospective Studies; Tacrolimus; Tissue Donors; Treatment Failure; Treatment Outcome; Withholding Treatment; Young Adult | 2017 |
A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Everolimus; Female; Humans; Kidney Neoplasms; Male; Middle Aged; Mucositis; Pneumonia; Prednisone; Treatment Outcome | 2017 |
High rate of event-free survival at 24 months with everolimus/RCHOP for untreated diffuse large B-cell lymphoma: updated results from NCCTG N1085 (Alliance).
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Everolimus; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Prednisone; Rituximab; Survival Rate; Vincristine | 2017 |
Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Etoposide; Everolimus; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Neoplasm Recurrence, Local; Prednisone; Rituximab; Vincristine; Young Adult | 2018 |
Prospective randomized study comparing everolimus and mycophenolate sodium in de novo kidney transplant recipients from expanded criteria deceased donor.
Topics: Aged; Antilymphocyte Serum; Cytomegalovirus Infections; Delayed Graft Function; Donor Selection; Everolimus; Female; Glomerular Filtration Rate; Graft Rejection; Humans; Immunosuppression Therapy; Immunosuppressive Agents; Incidence; Kidney; Kidney Failure, Chronic; Kidney Function Tests; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Prednisone; Prospective Studies; Risk Assessment; Risk Factors; Tacrolimus; Treatment Outcome | 2019 |
Use of mTOR inhibitor as prophylaxis for cytomegalovirus disease after kidney transplantation: A natural experiment.
Topics: Adult; Antilymphocyte Serum; Brazil; Cytomegalovirus; Cytomegalovirus Infections; Everolimus; Female; Follow-Up Studies; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Incidence; Kidney Transplantation; Male; Middle Aged; Postoperative Complications; Prednisone; Prognosis; Retrospective Studies; Risk Factors; Tacrolimus; TOR Serine-Threonine Kinases | 2019 |
Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses.
Topics: Antilymphocyte Serum; Basiliximab; Everolimus; Graft Rejection; Humans; Immunosuppressive Agents; Kidney Transplantation; Mycophenolic Acid; Prednisone; Prospective Studies; Tacrolimus | 2020 |
11 other study(ies) available for prednisone and everolimus
| Article | Year |
|---|---|
Everolimus but not mycophenolate mofetil therapy is associated with soluble HLA-G expression in heart transplant patients.
Topics: Adult; Aged; Area Under Curve; Cyclosporine; Drug Therapy, Combination; Everolimus; Female; Follow-Up Studies; Heart Transplantation; Histocompatibility Antigens Class I; HLA Antigens; HLA-G Antigens; Humans; Immunosuppressive Agents; Male; Maternal-Fetal Exchange; Middle Aged; Mycophenolic Acid; Prednisone; Pregnancy; Pregnancy Proteins; Sirolimus | 2009 |
Lipid profile changes during the first year after kidney transplantation: risk factors and influence of the immunosuppressive drug regimen.
Topics: Adult; Analysis of Variance; Biomarkers; Brazil; Chi-Square Distribution; Cyclosporine; Drug Therapy, Combination; Dyslipidemias; Everolimus; Female; Humans; Immunosuppressive Agents; Incidence; Kidney Transplantation; Lipids; Logistic Models; Male; Middle Aged; Mycophenolic Acid; Odds Ratio; Prednisone; Retrospective Studies; Risk Assessment; Risk Factors; Sirolimus; Tacrolimus; Time Factors; Treatment Outcome | 2011 |
[Association of everolimus with tacrolimus during the first year after heart transplantation: initial experience].
Topics: Antibodies, Monoclonal; Basiliximab; Calcineurin Inhibitors; Creatinine; Drug Therapy, Combination; Everolimus; Follow-Up Studies; Graft Rejection; Heart Transplantation; Herpes Zoster; Humans; Immunosuppressive Agents; Kidney Diseases; Prednisone; Recombinant Fusion Proteins; Retrospective Studies; Sirolimus; Stomatitis, Herpetic; Tacrolimus; Virus Activation | 2013 |
Malignant epithelioid angiomyolipoma: tumor and metabolic response to everolimus as evaluated with positron emission tomography.
Topics: Angiomyolipoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Everolimus; Humans; Immunosuppressive Agents; Kidney Neoplasms; Lymphoma, T-Cell; Male; Middle Aged; Positron-Emission Tomography; Prednisone; Radiography; Sirolimus; Vincristine | 2013 |
Three-yr safety and efficacy of everolimus and low-dose cyclosporine in de novo pediatric kidney transplant patients.
Topics: Adolescent; Antibodies, Monoclonal; Basiliximab; Child; Child, Preschool; Cyclosporine; Drug Administration Schedule; Drug Therapy, Combination; Everolimus; Female; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Kaplan-Meier Estimate; Kidney Transplantation; Male; Mycophenolic Acid; Prednisone; Prospective Studies; Recombinant Fusion Proteins; Sirolimus; Treatment Outcome | 2014 |
Posttransplant encapsulating peritoneal sclerosis, long-term success with everolimus and low-dose CNI: a case report.
Topics: Adult; Calcineurin Inhibitors; Cyclosporine; Drug Therapy, Combination; Everolimus; Female; Glucocorticoids; Humans; Immunosuppressive Agents; Intestinal Obstruction; Kidney Transplantation; Peritoneal Dialysis; Peritoneal Fibrosis; Prednisone; Sirolimus | 2014 |
Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients.
Topics: Adult; Antibodies; Cohort Studies; Drug Interactions; Drug Substitution; Everolimus; Female; Glomerular Filtration Rate; Humans; Immunosuppressive Agents; Kidney Transplantation; Male; Middle Aged; Mycophenolic Acid; Prednisone; Prospective Studies; Pyrroles; Quinazolines; Tacrolimus | 2016 |
Birth defects in juvenile Wistar rats after exposure to immunosuppressive drugs during pregnancy.
Topics: Abnormalities, Drug-Induced; Animals; Cyclosporine; Everolimus; Female; Immunosuppressive Agents; Mycophenolic Acid; Prednisone; Pregnancy; Prenatal Exposure Delayed Effects; Rats; Rats, Wistar; Tacrolimus | 2017 |
The influence of exposure to immunosuppressive treatment during pregnancy on renal function and rate of apoptosis in native kidneys of female Wistar rats.
Topics: Animals; Apoptosis; Creatinine; Cyclosporine; Everolimus; Female; Immunosuppressive Agents; Kidney; Kidney Function Tests; Mycophenolic Acid; Prednisone; Pregnancy; Rats; Rats, Wistar; Tacrolimus | 2016 |
Anti-tumor activity of selective inhibitor of nuclear export (SINE) compounds, is enhanced in non-Hodgkin lymphoma through combination with mTOR inhibitor and dexamethasone.
Topics: Acrylamides; Active Transport, Cell Nucleus; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Everolimus; Exportin 1 Protein; Humans; Hydrazines; Karyopherins; Lymphoma, Non-Hodgkin; Mice, Inbred ICR; Mice, SCID; Oxadiazoles; Prednisone; Protein Kinase Inhibitors; Receptors, Cytoplasmic and Nuclear; Signal Transduction; Thiazoles; Time Factors; TOR Serine-Threonine Kinases; Transcription Factor RelA; Triazoles; Tumor Burden; Vincristine; Xenograft Model Antitumor Assays | 2016 |
Extreme hypercalcemia in a kidney transplant recipient.
Topics: Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Everolimus; Fatal Outcome; Fluorodeoxyglucose F18; Humans; Hypercalcemia; Kidney Transplantation; Lymphoproliferative Disorders; Male; Positron-Emission Tomography; Prednisone; Renal Dialysis; Rituximab; Shock, Septic; Transplant Recipients; Vincristine | 2018 |